TScan Therapeutics (TCRX) Stock Insights
TCRX$0.19-0.00 -2.01%
$12.38M
Market Cap
-0.20
P/E
—
Forward P/E
56
Score
TScan Therapeutics (TCRX) Stock Insights
TCRX price $0.19 -0.00 -2.01%
- Ticker
- TCRX
- Price
- $0.19
- Change
- -0.00 -2.01%
- Market cap ?
- $12.38M
- P/E ?
- -0.20
- Dividend yield ?
- 0.00%
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 56
- Value
- 59
- Quality
- 46
- Growth
- 62
Stocklytics score rationale: value 59, quality 46, growth 62.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 1085000 | 10141000 | 13535000 | 21049000 | 2816000 | 10325000 |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell…
Insights · Dividends · Forecast · Financials · Learn